Neon Therapeutics (NTGN)

[ALERTS100%to10000%GAIN]

The findings in the Immunity publication demonstrate that Neon’s proprietary class II prediction algorithms substantially outperform NetMHCIIpan, the current benchmark for class II prediction. Key findings in the research include the development of novel proteomic strategies that resolve over 40 MHC class II motifs and the observation that intra-tumoral MHC class II presentation is dominated by professional antigen presenting cells (APCs) rather than tumor cells. Tracking which tumor epitopes are most readily phagocytosed and presented by APCs further enhances the ability to pinpoint therapeutically relevant epitopes.

A proprietary approach powering Neon’s RECON bioinformatics platform for MHC class I molecules was first described in an earlier article published in Immunity in 2017.